Harrow Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. (HROW) on December 17, 2021. The filing details a strategic expansion into the ophthalmic market through a definitive agreement with Novartis.
Key Financial Metrics and Transaction Details
The primary financial event reported is the acquisition of exclusive U.S. commercial rights to three ophthalmic products: Moxeza, Iopidine, and Maxitrol.
- Upfront Payment: $14,050,000 paid to Novartis on the closing date.
- Revenue Model: For up to six months post-closing, Novartis will sell the products on Harrow's behalf, transferring net profits to the Company.
- Debt and Liquidity: The filing does not provide updated figures for total debt, cash flow, or liquidity ratios following this transaction.
Material Changes
The most significant change is the entry into an Asset Purchase Agreement with Novartis Technology, LLC and Novartis Ophthalmics AG. This agreement grants Harrow Health exclusive rights to the specified ophthalmic products in the United States, marking a shift in the company's product portfolio.
Outlook, Risks, and Management Commentary
Management has outlined a transition period where Novartis will continue sales operations for up to six months while New Drug Applications (NDAs) are transferred to Harrow. Novartis has also agreed to assist with technology transfer to third-party manufacturers if necessary. The full text of the agreement is expected to be filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2021.
Investor Verification Checklist
- Verify the impact of the $14.05 million cash outflow on the company's current liquidity position.
- Review the upcoming Form 10-K for the full Asset Purchase Agreement and specific terms regarding the six-month transition period.
- Monitor the timeline for the transfer of New Drug Applications (NDAs) from Novartis to Harrow Health.
- Assess the projected net profit margins from the ophthalmic products once Harrow assumes full commercial control.